2026-04-17T14:12:30Zhttps://recercat.cat/oai/request
oai:recercat.cat:2445/2085562025-12-05T13:07:36Zcom_2072_1057col_2072_478798col_2072_478916col_2072_478917
RECERCAT author Mosteiro, Miguel author Azuara García, Daniel author Alay, Ania author Gausachs Romero, Mireia author Varela Rodríguez, Mar author Baixeras, N. author Pijuan, Lara author Ajenjo-Bauza, M. author López Dóriga Guerra, Adriana author Teulé-Vega, Àlex author Solanes, Aleix author Palmero, Ramón author Brenes, Jesús author Jové, M. author Padrones, Susana author Moreno Aguado, Víctor author Cordero, D. author Matias-Guiu, Xavier, 1958- author Lázaro García, Conxi author Nadal, Ernest 2024-03-08T18:24:14Z2024-03-08T18:24:14Z2023-12-012024-03-08T18:24:14Z Background: Targeted next-generation sequencing (NGS) is recommended to screen actionable genomic alterations (GAs) in patients with non-small-cell lung cancer (NSCLC). We determined the feasibility to detect actionable GAs using TruSight™ Oncology 500 (TSO500) in 200 consecutive patients with NSCLC. Materials and methods: DNA and RNA were sequenced on an Illumina® NextSeq 550 instrument and processed using the TSO500 Docker pipeline. Clinical actionability was defined within the molecular tumour board following European Society for Medical Oncology (ESMO) guidelines for oncogene-addicted NSCLC. Overall survival (OS) was estimated as per the presence of druggable GAs and treatment with targeted therapy. Results: Most patients were males (69.5%) and former or current smokers (86.5%). Median age was 64 years. The most common histological type and tumour stage were lung adenocarcinoma (81%) and stage IV (64%), respectively. Sequencing was feasible in most patients (93.5%) and actionable GAs were found in 26.5% of patients. A high concordance was observed between single-gene testing and TSO500 NGS panel. Patients harbouring druggable GAs and receiving targeted therapy achieved longer OS compared to patients without druggable GAs. Conversely, patients with druggable GAs not receiving targeted therapy had a trend toward shorter OS compared with driver-negative patients. Conclusions: Hybrid capture sequencing using TSO500 panel is feasible to analyse clinical samples from patients with NSCLC and is an efficient tool for screening actionable GAs. cc-by-nc-nd (c) European Society for Medical Oncology, CH, 2023 http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Càncer de pulmó Genòmica Estudis de viabilitat Lung cancer Genomics Feasibility studies Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centre info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion